---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-014729"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-09-24T23:59:59+00:00"
generated_at: "2026-05-17T05:49:04.071108+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology awarded $2.3M NIH grant for THIO-101 Phase 2 trial in NSCLC

## Summary
- NIH grant of $2.3M supports expansion of THIO-101 Phase 2 trial evaluating ateganosine as third-line NSCLC treatment.
- Grant funds enrollment of US patients resistant to chemo/immunotherapy; distributed over 3 years (2025-2027).
- First US patient enrollment to begin immediately following 2023 FDA IND clearance; first expansion patient dosed July 2025 in Taiwan.
- Median overall survival for 22 third-line patients was 17.8 months (June 30, 2025) vs 5-6 months for standard chemo.
- Grant is non-dilutive funding from NIH's National Cancer Institute (Award R44CA309843).

## SEC filing metadata
- accession: 0001493152-25-014729
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-09-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315225014729/0001493152-25-014729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315225014729/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-014729
- JSON: https://secwatch.observer/filing/0001493152-25-014729.json
- Plain text: https://secwatch.observer/filing/0001493152-25-014729.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.